Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab dose reduction or interval prolongation in systemic juvenile idiopathic arthritis
NL-OMON44923Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Feb 2015; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NL-OMON44923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44923.